Scientific Sharing | DDC-induced Primary Sclerosing Cholangitis Model

Introduction

Primary sclerosing cholangitis (PSC)is a chronic fibrosing inflammatory cholangiopathy that affects the intrahepatic and/or extrahepatic bile ducts. Closely linked to inflammatory bowel disease and associated with cholangiocarcinoma risk, PSC features a complicated etiology with incompletely understood pathogenesis. There is a lack of targeted specific therapies in current clinical practice. Liver transplantation remains the major therapeutic option for end‑stage patients, yet it carries a high recurrence rate and markedly increases the risk of cholangiocarcinoma, making PSC a highly challenging refractory disease in hepatobiliary medicine.Unraveling disease mechanisms, identifying new drug targets, and conducting in vivo pharmacodynamic assessment of candidate drugs strongly depend on preclinical animal models that can faithfully recapitulate the key pathological hallmarks of human PSC.

Come take a look
In this issue, we will take you through an in-depth introduction to the DDC-induced primary sclerosing cholangitis model, to support advanced new drug development and guide clinical trials.

 

Regarding the DDC-induced primary sclerosing cholangitis model

1 Key Disease Features of PSC
Primary sclerosing cholangitis (PSC) is clinically characterized by multifocal biliary strictures and dilatation, producing a beaded appearance of the bile ducts. Histologically, it presents with concentric “onion‑skin” periductal fibrosis, fibro‑obliterative cholangitis, and progressive loss of bile ducts.
2 Mechanism of DDC Induction
DDC (3,5-Diethoxycarbonyl-1,4-dihydro-2,4,6-collidine) promotes the excretion of porphyrins into bile, which form crystals or plug‑like deposits within the biliary lumen, triggering segmental biliary obstruction, biliary epithelial injury and reactive ductular proliferation. Sustained or repeated injury further provokes periductal inflammation, myofibroblast activation and periductal collagen deposition, leading to sclerosing cholangitis‑like lesions. Classic DDC studies have demonstrated that,This model can induce ductular reaction, pericholangitis and periductal fibrosis within a relatively short time frame.
3 Matching Degree with PSC Indications

4 Suitable Drug Types for the Model
·Suitable for evaluating biliary protection, inhibition of ductular reaction, amelioration of cholestasis, anti‑inflammatory activity and anti‑periductal fibrosis effects.
·Suitable for mechanistic validation of candidate drugs targeting bile acid metabolism, FXR/FGF19, ASBT, biliary epithelial homeostasis and fibrotic signaling pathways.
·Not suitable for standalone demonstration of disease‑modifying effects on PSC‑IBD, multifocal strictures of large extrahepatic bile ducts or cholangiocarcinoma risk.
5 Platform Model Design and Scientific Positioning
KCI Biotech has established and completed platform validation of a modified DDC intragastric mouse model.The model employs oral DDC gavage with continuous induction for four weeks. While this administration route differs from the conventional DDC mixed‑diet method widely documented in published literature, the disease‑inducing compound and core mechanisms of biliary injury remain consistent. It can offer strong support for research into the pathogenesis of primary sclerosing cholangitis, drug discovery, and safety assessment of clinical medications.

 

Case Sharing of the DDC‑Induced PSC Model and Pharmacodynamic Evaluation in C57BL/6J Mice

Data Presentation
·Serum Biochemical Assays | Markers of Hepatocellular Injury and Cholestasis


·Objective Quantitative Endpoints for Gross Phenotypes

·Histopathology | H&E Staining, SR Staining

 

KCI・KMQ Gastrointestinal Disease Pharmacology and Efficacy Evaluation Platform

The KCI・KMQ Gastrointestinal Disease Pharmacology and Efficacy Evaluation Platform boasts a comprehensive animal model system. With rich accumulated project experience, the platform can meet diversified research demands.At present, the company has established extensive long‑term collaborations with numerous well‑known pharmaceutical enterprises and research institutions at home and abroad, laying a solid foundation for the development of innovative drugs.

 

Conclusion

The successful establishment of PSC animal models serves as a critical link bridging basic research and clinical translation. Their stability and reliability provide robust support for investigations into PSC pathogenesis, drug development, and safety assessment of clinical medications.The animal disease models of KCI・KMQ play an essential role in this field. Supported by professional model establishment and evaluation systems, KCI・KMQ continues to deliver powerful services for research institutes and pharmaceutical companies, jointly accelerating the translational progress from fundamental understanding to therapeutic breakthroughs for PSC.

Leave a Reply

Your email address will not be published. Required fields are marked *